» Articles » PMID: 32488958

Analysis of Clinical Features and Outcomes of 161 Patients with Severe and Critical COVID-19: A Multicenter Descriptive Study

Overview
Journal J Clin Lab Anal
Publisher Wiley
Date 2020 Jun 4
PMID 32488958
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study aimed to investigate clinical characteristics, laboratory indexes, treatment regimens, and short-term outcomes of severe and critical coronavirus disease 2019 (COVID-19) patients.

Methods: One hundred and sixty one consecutive severe and critical COVID-19 patients admitted in intensive care unit (ICU) were retrospectively reviewed in this multicenter study. Demographic features, medical histories, clinical symptoms, lung computerized tomography (CT) findings, and laboratory indexes on admission were collected. Post-admission complications, treatment regimens, and clinical outcomes were also documented.

Results: The mean age was 59.38 ± 16.54 years, with 104 (64.60%) males and 57 (35.40%) females. Hypertension (44 [27.33%]) and diabetes were the most common medical histories. Fever (127 [78.88%]) and dry cough (111 [68.94%]) were the most common symptoms. Blood routine indexes, hepatic and renal function indexes, and inflammation indexes were commonly abnormal. Acute respiratory distress syndrome (ARDS) was the most common post-admission complication (69 [42.86%]), followed by electrolyte disorders (48 [29.81%]), multiple organ dysfunction (MODS) (37 [22.98%]), and hypoproteinemia (36 [22.36%]). The most commonly used antiviral drug was lopinavir/ritonavir tablet. 50 (31.06%) patients died, while 78 (48.45%) patients healed and discharged, and the last 33 (20.50%) patients remained in hospital. Besides, the mean hospital stay of deaths was 21.66 ± 11.18 days, while the mean hospital stay of discharged patients was 18.42 ± 12.77 days. Furthermore, ARDS (P < .001) and MODS (P = .008) correlated with increased mortality rate.

Conclusion: Severe and critical COVID-19 presents with high mortality rate, and occurrence of ARDS or MODS greatly increases its mortality risk.

Citing Articles

Construction of geriatric hypoalbuminemia predicting model for hypoalbuminemia patients with and without pneumonia and explainability analysis.

Liu Z, Kang Q, Mi Z, Yuan Y, Sang T, Guo B Front Med (Lausanne). 2025; 11():1518222.

PMID: 39811157 PMC: 11729439. DOI: 10.3389/fmed.2024.1518222.


Active cancer as the main predictor of mortality for COVID-19 in oncology patients in a specialized center.

Villanueva-Cotrina F, Velarde J, Rodriguez R, Bonilla A, Laura M, Saavedra T Pathol Oncol Res. 2023; 29:1611236.

PMID: 37746553 PMC: 10511753. DOI: 10.3389/pore.2023.1611236.


Neurological complications and effects of COVID-19: Symptoms and conceivable mechanisms.

Sarioglu E, Sarialtin S, Coban T Brain Hemorrhages. 2023; 4(3):154-173.

PMID: 36789140 PMC: 9911160. DOI: 10.1016/j.hest.2023.02.001.


Moraxella occupied the largest proportion in the nasal microbiome in healthy children, which potential protect them from COVID-19.

Yu X, Wang L, Zheng X, Wen Y, Zhang Z, Fan L Microb Pathog. 2022; 170:105685.

PMID: 35870694 PMC: 9299982. DOI: 10.1016/j.micpath.2022.105685.


Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.

Degarege A, Naveed Z, Kabayundo J, Brett-Major D Pathogens. 2022; 11(5).

PMID: 35631084 PMC: 9147100. DOI: 10.3390/pathogens11050563.


References
1.
Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q . Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol. 2020; 127:104371. PMC: 7195434. DOI: 10.1016/j.jcv.2020.104371. View

2.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

3.
Peiris J, Chu C, Cheng V, Chan K, Hung I, Poon L . Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361(9371):1767-72. PMC: 7112410. DOI: 10.1016/s0140-6736(03)13412-5. View

4.
Azhar E, Hui D, Memish Z, Drosten C, Zumla A . The Middle East Respiratory Syndrome (MERS). Infect Dis Clin North Am. 2019; 33(4):891-905. PMC: 7127753. DOI: 10.1016/j.idc.2019.08.001. View

5.
Cho S, Kang J, Ha Y, Park G, Lee J, Ko J . MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study. Lancet. 2016; 388(10048):994-1001. PMC: 7159268. DOI: 10.1016/S0140-6736(16)30623-7. View